Actavis debuts generic Pariet in Europe; Impax challenges Opana ER patent

18 November 2012

Switzerland-based generic drugmaker Actavis, now wholly-owned by the USA’s Watson Pharmaceuticals (NYSE: WPI), last Friday announced the launch of the proton pump inhibitor rabeprazole in Germany, France, Spain, the Netherlands and UK immediately after the patents expired on 12-13 November. The product will be launched in Italy shortly. In Austria, Actavis started the pricing process on day one.

Developed and manufactured by Actavis in Iceland, Rabeprazole Sodium Actavis is the generic equivalent of Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Pharmaceuticals' brand product Pariet. According to IMS Health data quoted by Actavis, branded rabeprazole sales in Europe were 305 million euros ($388 million) for the year ending June 2012.

Impax and ThoRx Laboratories confirm Opana ER patent challenge

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK